Skip to content


  • Poster presentation
  • Open Access

Recruiting patients cost-effectively by mail

  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Trials201112 (Suppl 1) :A117

  • Published:


  • Aspirin
  • Cardiovascular Event
  • Research Network
  • Clinical Staff
  • National Information


Large randomised trials have been successfully conducted using mailed drug supply and follow-up [14] . ASCEND (A Study of Cardiovascular Events iN Diabetes) is a randomised “2x2 factorial design” study of aspirin versus placebo and of omega-3 fatty acid versus placebo, for the primary prevention of cardiovascular events in people with diabetes. In order to be able to study 15,000 people with diabetes for about 7 years at low cost, ASCEND is streamlined and run mainly by mail with back-up from a 24-hour Freefone service.


In collaboration with consultants around the UK, potentially eligible people with diabetes have been identified from various sources including: centrally-held registers (e.g.: Retinopathy screening registers); GP-held local registers and self-referral via a website. For patients identified from centrally-held registers, permission was gained from the National Information Governance Board to allow centrally generated letters in the name of the holder of the register, to be sent to patients listed on registers. In addition, with the collaboration of the Diabetes Research Network and the Primary Care Research Network, 730 general practices agreed to send pre-assembled invitation packs to people on their locally held registers.

To facilitate recruitment, the design is straightforward with simple inclusion and exclusion criteria and treatment packaged for easy mailing. Double sided A3 forms are used for screening, randomisation and follow-up. On the Screening form, patients confirm their eligibility and consent that they are happy to take part by ticking a series of boxes. If they have any questions then they can telephone study staff via a Freefone number. Screening forms of those entering the study are checked centrally by clinical staff. Patients enter a 2-month pre-randomisation run-in phase and are randomised if they complete a randomisation form and remain willing and eligible.


In total, 423,286 people with diabetes were invited to take part and 15,481 randomised (see table).

Table 1


Centrally-held register

GP practices (Local register)



Invitations sent





Patients enter run-in





Patients randomised

9013 (3.0%)

6038 (5.0%)

430 (19.3%)

15481 (3.7%)

* HPS follow up/Self/friends/Hospital referral


If sufficient numbers of potentially eligible patients can be identified centrally and trial treatments require little in the way of monitoring, the recruitment and follow-up of patients in clinical trials by mail is feasible and cost-effective. Wider use of these methods could allow more large randomised trials to be undertaken successfully and cost-effectively.

Authors’ Affiliations

Clinical Trial Service Unit, University of Oxford, Oxford, OX3 7LF, UK


  1. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K: Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988, 296 (6618): 313-6. 10.1136/bmj.296.6618.313.View ArticleGoogle Scholar
  2. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989, Steering Committee of the Physicians' Health Study Research Group, 321 (3): 129-35.Google Scholar
  3. Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE: Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med. 2000, 9 (1): 19-27. 10.1089/152460900318911.View ArticlePubMedGoogle Scholar
  4. Christen WG, Gaziano JM, Hennekens CH: Design of Physicians' Health Study II-a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol. 2000, 10 (2): 125-34. 10.1016/S1047-2797(99)00042-3.View ArticlePubMedGoogle Scholar


© Aung et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.